COMMUNIQUÉS West-GlobeNewswire

Syncromune to Present Updated Long-Term Overall Survival Data from Phase 1 Trial of SYNC-T Therapy SV-102 in Metastatic Prostate Cancer at ESMO Congress 2026
19/10/2026
FORT LAUDERDALE, Fla., and WEST DES MOINES, Iowa, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™ an investigational in situ multi-target [...]
Rivus Pharmaceuticals to Present Preclinical Obesity Data for Muscle-Preserving, Oral GLP-1 RV-8451 at ObesityWeek®
19/10/2026
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health, today [...]
Medera's Novoheart Technology Powers Advanced Human Cardiac Disease Modeling at Singapore's New CIPHER Research Centre
19/10/2026
National Heart Centre Singapore's new research centre integrates Novoheart's proprietary Heart-in-a-Jar technology with patient-derived cardiac disease models to advance cardiovascular research and drug discovery [...]
Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET
19/10/2026
LAGUNA HILLS, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it [...]
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
19/10/2026
Latest addition to Resmed’s growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD [...]
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
19/10/2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature [...]
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
19/10/2026
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients [...]
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
19/10/2026
• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers SYDNEY, AUSTRALIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Immutep [...]
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
19/10/2026
TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) is pleased to announce the publication of a new corporate presentation, now [...]
Novo Nordisk A/S - share repurchase programme
19/10/2026
Bagsværd, Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Ritedose Partners with Newberry College to Launch Leadership Development Program
19/10/2026
Organizational development and pharmaceutical leadership certificate is designed to strengthen organizational leadership at Ritedose COLUMBIA, S.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) [...]
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
19/10/2026
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application ( [...]
Transactions under Novonesis’ share buyback program
19/10/2026
Please read the announcement in PDF Attachment 2026_22_Share_buyback
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/10/2026
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Prime Minister Mark Carney Sends Greetings as Canada Lights Up Sea-foam Green for International Stuttering Awareness Day
19/10/2026
From Niagara Falls to the CN Tower, landmarks across Canada will shine sea-foam green on October 22 as Canadians call for greater understanding and acceptance of stuttering. TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
19/10/2026
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedented two-year data from the trial including a 75% Objective Response [...]
RAMSAY GENERALE DE SANTE : Availability of the 2026 URD - Evolution in the Governance - Annual General meeting on 4th December 2026
19/10/2026
PRESS RELEASE Paris, 19 October 2026 EVOLUTION IN THE GOVERNANCE OF RAMSAY GENERALE DE SANTE AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT ANNUAL GENERAL MEETING ON 4 DECEMBER 2026 Ramsay Health Care Limited [...]
RAMSAY GENERALE DE SANTE : Evolution de la gouvernance - Mise à disposition du DEU 2026 - Assemblée Générale du 4 décembre 2026
19/10/2026
COMMUNIQUÉ DE PRESSE Paris, le 19 octobre 2026 EVOLUTION DE LA GOUVERNANCE DE RAMSAY GENERALE DE SANTE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2026 ASSEMBLEE GENERALE DU 4 DECEMBRE 2026 Il est rappelé [...]
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
19/10/2026
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum